Lilly Links Up with InduPro in Next-Gen Cancer Treatment Deal Worth Up to $950M

InduPro has partnered with Eli Lilly to discover new cancer therapies using its AI/ML-enabled membrane interactomics platform. InduPro will lead early discovery on up to three undisclosed targets. The collaboration could reach $950M and includes a Lilly equity investment, reinforcing confidence in InduPro’s tumor-selective, multispecific oncology approach.